Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines

•
We accept pre-submission inquiries
•
Our selector tool helps you to find the most relevant journal
•
We provide round the clock customer support 
•
Convenient online submission
•
Thorough peer review
•
Inclusion in PubMed and all major indexing services 
•
Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
essential for the biosynthesis of oxygenated mycolic acids in Mycobac-
terium tuberculosis. J Biol Chem. 2006;281:4434–45.
131. Procop GW. HIV and mycobacteria. Semin Diagn Pathol. 2017;34:332–9.
132. Perronne C, Zahraoui M, Leport C, Salmon D, Pangon B, Bricaire F, Vilde 
JL. Tuberculosis in 30 patients with HIV infection. Ann Med Interne. 
1988;139:375–6.
133. Haegi V. Septic tuberculosis in HIV-infection. Schweiz Med Wochenschr. 
1987;117:1297–301.
134. Martin-Bertelsen B, Korshohn KS, Roces CB, Nielsen MH, Christensen 
D, Franzyk H, Yaghmur A, Foged C. Nano-self-assemblies based on 
synthetic analogues of mycobacterial monomycoloyl glycerol and 
DDA: supramolecular structure and adjuvant efficacy. Mol Pharm. 
2016;13:2771–81.
135. Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, 
de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a 
lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 
2017;35:1395–402.

---

Document Outline

• Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
  • Abstract 
  • Background
  • Liposome design
    • Liposomal vesicle size
    • Lamellarity nature of the liposome
    • Surface charge
    • Bilayer fluidity
    • Immunostimulatory lipids and liposome deposition
  • Liposome-immune cell interactions to improve vaccine effectiveness
    • Vaccine interaction with neutrophils, monocytes and APCs
    • Mannosylated liposomes
  • Viral infections and liposomes-based vaccines
    • Hepatitis
    • Influenza
    • Respiratory syncytial virus
  • Bacterial infections and liposomal vaccines
  • Liposomal-based vaccines in fungal infection treatment
  • Parasitic infections and liposomal vaccines
    • Parasitism and malaria
    • Amoebiasis
  • DDA-based cationic liposomal vaccines for the treatment of tuberculosis
  • Conclusion
  • Authors’ contributions
  • References